cyrilzakka/clinical-trials huggingface dataset:
Combining VNS with PT Interventions for Individuals with PD

The purpose of this study is to evaluate the combined effects of non-invasive neuromodulation (specifically transauricular Vagus Nerve Stimulation) with exercise interventions to improve physical function and quality of life in individuals with Parkinson\&#39;s Disease.

During this clinical trial, participants will be randomized into two groups, with half of the participants assigned to GROUP 1: active taVNS + exercise, and half of the participants assigned to GROUP 2: sham taVNS + exercise. The active taVNS + exercise group will receive 15 minutes of active taVNS prior to treatment. Participants who are randomized into the sham taVNS + exercise group will receive 0 mA of current for 15 minutes prior to treatment. All participants will be guided through exercises by a licensed physical therapist, which will include: 1) intensive exercises that focus on increasing the size and amplitude of movements; 2) task-specific practice, which involves practicing functional tasks, such as dressing, bathing, and cooking, in order to transfer the gains made in therapy to real-life situations. The exercise intervention proposed involves the supervision of a licensed PT at all times during the treatment session. Exercise will be provided in a clinical setting, 45 minutes per session, up to 3 sessions/week, for 4-6 weeks total.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of PD by a board-certified neurologist
* age between 35 and 80 years
* no walking aids
* stable medication 4 weeks prior to and during the study
* no falls in the past 6 months
* participant must have MD who is willing to provide oversight and approval for clinically defined \&#34;off\&#34; state

Exclusion Criteria:

* mild cognitive impairment (MoCA \&lt;25)
* self reported depression
* antidepressive or antipsychotic medication
* participation in a VNS study in the past year
* disabling bradykinesia to ensure patients are able to participate in intensive physiotherapy (based on clinical impression and in accordance to UPDRS part III item 14 - to be administered in clinic)
* prior history of cardiovascular, neurological or musculoskeletal disorders known to interfere with testing PD features
* implanted medical device of any type
* history of seizures
* peripheral neuropathy including temporal mandibular disorders and Bells Palsy, and
* vasovagal syncope.
Effectiveness of an Online Prevention Program in Reducing the Risk of STD Infection in Young Adults

This study will evaluate the effectiveness of a tailored interactive online risk reduction program versus a standard online risk reduction program in reducing the risk of Sexually Transmitted Diseases (STD) infection in young adults.

Adolescents and young adults are at the greatest risk for acquiring an STD. Approximately 3 million people between the ages of 18 and 24 become infected each year. Education about the risks and consequences of unprotected sex is a powerful tool that can be used to prevent or reduce the risk of infection. The program in this study will deliver messages to educate participants about condom use and the risk of STD infection. This study will evaluate the effectiveness of a tailored interactive online risk reduction program versus a standard online risk reduction program in reducing the risk of STD infection in young adults.

Participants in this 1-year open-label study will be recruited exclusively via the internet. Participants will be randomly assigned to receive internet-based messages from either the Youthnet program or the control program. Messages from the Youthnet program will be interactive and tailored specifically to Human Immunodeficiency Virus/Sexually Transmitted Diseases (HIV/STD) risk reduction. The control program will deliver standard STD/HIV prevention messages. Participants will be assessed at baseline and a follow-up session 4 months after enrollment. Frequency of condom use and attitudes toward condom use will be assessed using behavioral scales.

Eligibility Criteria:
Inclusion Criteria:

* Has access to the internet
* Has an e-mail address

Exclusion Criteria:

* Colorado resident
The Effect of no Muscle Relaxant Versus Reduced-dose Rocuronium on Anesthesia in Adenotonsillectomy

This study aimed to compare the effect of no muscle relaxants and reduced-dose rocuronium on the anesthetic induction and emergence with fentanyl in children undergoing adenotonsillectomy.

Adenotonsillectomy in children is a short surgical procedure under general anesthesia. The ideal muscle relaxant requires intense neuromuscular block for optimal surgical work and complete recovery of neuromuscular function immediately after the end of the surgical procedure without postoperative morbidity. Rocuronium is an intermediate acting neuromuscular blockade. Reduced-dose rocuronium has been reported to provide optimal anesthetic induction without delayed recovery. The investigators aimed to compare the effect of no muscle relaxants and reduced-dose rocuronium on the anesthetic induction and emergence with fentanyl in children undergoing adenotonsillectomy.

After Institutional Review Board approval and written informed consent from the parents were obtained, 75 children (aged 3 to 10 years, ASA(The American Society of Anesthesia ) I or II) scheduled for adenotonsillectomy were included. Anesthesia was induced with propofol 2.5 mg kg-1 , fentanyl 2 mcg kg-1, and rocuronium 0.15 mg kg-1 (R 0.15 group) or rocuronium 0.3mg kg-1 (R 0.3 group) or saline (S group). After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done. The investigators assessed conditions during tracheal intubation as excellent, good or poor, using five variables; jaw relaxation, vocal cord position, vocal cord movement, coughing, and movement of the limbs. The investigators added rocuronium 0.3 mg kg-1 when there was more than one poor condition. The investigators recorded the time from discontinuation of sevoflurane to time to extubation.

Eligibility Criteria:
Inclusion Criteria:

* American Society of Anesthesiologist\[ASA\] class 1-2
* scheduled adenotonsillectomy
* written informed consent

Exclusion Criteria:

* allergy of opioids, neuromuscular blocking drugs or other medications used during general anesthesia
* known or suspected upper respiratory infection
* disorder affecting neuromuscular blockade
* suspected difficult tracheal intubation
* Developmental Disability
* known or suspected psychologic disorder
* medication (psychoactive drugs)
"Medikidz Explain JIA Comic Book- Hebrew"

We believe, that the results of this study will show that children learn from the comic book about their disease, and are now more aware and less frightened about it, and increase their compliance.

We believe, that the results of this study will show that children learn from the comic book about their disease, and are now more aware and less frightened about it, and increase their compliance. If so, it may promote the use of comic books or other fun educational tool in teaching children various other diseases.

Eligibility Criteria:
Inclusion Criteria:

Children with JIA aged 10-18 after parents signed ICF

Exclusion Criteria:

Parents that do not wanf their children to participate in the study.
Chronic Obstructive Pulmonary Disease (COPD) Monitoring

The present feasibility study aims at assessing whether the EMG of respiratory muscles can serve as an objective marker of dyspnea in COPD patients.

The study aims also at evaluating the changes in physiological parameters (i.e., EMG, respiration rate, heart rate, temperature, and SpO2) occurring when simulating daily activities before, during and after acute exacerbations. All this information can be useful to detect the exacerbations earlier or to provide better treatment during the exacerbations.


Eligibility Criteria:
Inclusion Criteria:

* Subject must have a clinical diagnosis of COPD
* mMRC (Modified Medical Research Council) Dyspnea Scale Score \> 1
* Subject must be indicated for regular inpatient pulmonary rehabilitation
* Subject must be hyperinflated, defined as residual volume (RV)\>120% of the predicted value, measured by whole body plethysmography
* Subject must be willing to provide Informed Consent for their participation in the study
* Subject must be ≥18 years of age

Exclusion Criteria:

* Subjects who are unable/unwilling to voluntarily participate in the study
* Subjects who cannot read/write
* Subjects who are dependent on oxygen and/or unfit to wear a mask during sub- maximal constant work rate test (CWRT)
* Subject has congenital heart disease
* Subject has unstable coronary artery disease
* Subject has an active implanted cardiac device (i.e. IPG, ICD)
* Subject has heart failure NYHA 4
* Subject presents any concomitant condition which in the opinion of the investigator would not allow a safe participation in the study
* Subject is legally incompetent
* Subject is pregnant or has suspect to be pregnant
* Subject is enrolled in a concurrent study that may confound the results of this study without documented pre-approval from Medtronic study manager
* BORG scale assessment is evaluated as unreliable due to patient's cognitive condition
Comparing Brief Relaxation Period to Virtual Reality Period in Reducing Dental Anxiety Prior to Root Canal Treatment

The goal of this study is to evaluate non-drug approaches to reducing dental anxiety prior to non-surgical root canal treatment. This will be done by comparing two relaxation methods which will be performed immediately prior to scheduled, clinical non-surgical root canal treatment. Measures of anxiety will be evaluated prior to, and after, the relaxation intervention, as well as after the non-surgical root canal treatment is completed. Participation in the study is completed in a single study visit.

Fifty-eight participants who needed non-surgical root canal treatment were randomly assigned into 2 groups of ABR and VRR. One group received earphones to listen to a guided brief relaxation recording, focusing on a body scan of tense points with diaphragmatic breathing. The other group received Meta 2 virtual reality headsets to listen and watch a 360 inclusive and integrative experience of ambient music, high resolution graphic illustrations and immersive scenery. Participants self-reported levels of anxiety were assessed prior to and post treatment by conducting evaluations using the State Trait Anxiety Indicator (STAI-State \& Trait) and the use of both a self-reported Visual Analog Scale (VAS) as well as by assessing objective secondary biometrics of anxiety of heart rate (HR) and Blood Pressure (BP) pre intervention, post intervention and following treatment completion.

Eligibility Criteria:
Inclusion Criteria:

* requires non-surgical root canal treatment
* is able to independently provide informed consent for root canal treatment
* proficient in English

Exclusion Criteria:

* history of vertigo or severe motion sickness
* history of severe psychiatric disease
* history of seizures, concussions, or severe neurological conditions
* visual or hearing impairments
* cardiac pacemaker or defibrillator
* will require nitrous oxide sedation, nor pharmacologic anxiolytics or sedatives for dental treatment
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different from sporadic lymphomas and to attempt to identify a gene that confers an increased risk of lymphoma.

* Patients who participate will be asked to complete detailed family and medical history questionnaires initially, with a follow-up questionnaire every year.
* Patients will be asked to supply a blood sample and possibly a mouthwash sample, both of which can be done by mail.
* Patients will be asked to consent to the release of their lymphoma tissue block for the purposes of the study.
* Patients will be given letters of invitation for their affected relatives to invite them to participate.

Eligibility Criteria:
Inclusion Criteria:

* Any individual diagnosed with non-Hodgkin's lymphoma or Hodgkin's disease or chronic lymphocytic leukemia (CLL), who has a 1st degree relative (parent, sibling or child) with a lymphoproliferative disorder; or families in which the individual has a lymphoproliferative disorder, and an unusual clustering of frequent or premature solid tumors is also observed.
* Family members of the individual, either affected or unaffected with lymphoma, who are contacted by the individual and agree to participate in the study.
* Deceased family members may be included in the study. Public records such as death certificates may be used to confirm the history. Consent for medical records or tissue blocks will be obtained from the deceased family member's next of kin. The hierarchy of relatives defined as next of kin is spouse, offspring, parents and siblings. Archived tissue samples may be used for genetic research.
* Age \> 18 years

Exclusion Criteria:

* Subjects without a family history of lymphoma
Personalized Pharmacotherapy Using Pharmacogenetics in Veterans

This study is an observational clinical trial aimed at to evaluate the use of pharmacogenetic testing (PGx) for mental health treatment in members and Veterans of the CAF and RCMP patient population as well as the attitudes of both St. Joseph's OSI Clinic Psychiatrists and patients towards PGx. Both OSI Clinic Psychiatrists participants and patient participants will be administered a brief demographic survey in addition to a survey examining their views on, and current knowledge of PGx. Patient participants will have an opportunity to opt-in to or opt-out of receiving PGx. For patient participants who opt-in to PGx (PGx-guided treatment group), a report summarizing the PGx results will be sent to each patient participants' respective OSI Clinic Psychiatrist, alongside a questionnaire that captures the OSI Clinic Psychiatrist participant's treatment planning and changes to treatment planning. Where applicable, past treatment data from patient participants acquired at the St. Joseph's OSI Clinic will be used to identify the number of prior medication changes. Patient participants who opt-out of PGx but continue to receive pharmacologic care at the St. Joseph's OSI Clinic will act as a standard care comparator treatment group. Patient participant's outcomes including PTSD, depression and anxiety severity, and medication-related side effects, will be assessed until the patient participant is discharged from the OSI Clinic or after 24 weeks, whichever comes first. All patient participants, regardless of their study treatment group, will have their symptomatology collected via standard care data collection protocol (Client Reported Outcomes Monitoring Information System (CROMIS) and electronic medical records (EMR)); a self-report assessing the presence of side effects will be completed via Lawson REDCap. OSI Clinic Psychiatrist participants and patient participants will be asked to complete a virtual exit interview at the end of their participation.


Eligibility Criteria:
Inclusion Criteria:

* Provider participant:

  * Are at least 18 years of age;
  * Speak and write English;
  * Currently working as an OSI Clinic Psychiatrist at the London St. Joseph's OSI Clinic.

    * Psychiatrist with an active caseload of patients being treated for OSIs.
* Patient participant:

  * Veteran (patient) CAF or RCMP member;
  * Are at least 18 years of age;
  * Are a current patient at the London St. Joseph's OSI Clinic;
  * Current diagnosis of an OSI;
  * Speak and write English;
  * Consents to the use of CROMIS data for the purpose of this study; and
  * Consents to the use of prior OSI Clinic data for research purposes (if you have been a patient at the OSI Clinic prior to this study, the research team will use past OSI Clinic data to observe changes over time).

Exclusion Criteria:

* Participants (provider or patients) who are unable to, or do not, provide informed consent for participation.
The Effects of Lycopene on High Risk Prostatic Tissue

The purpose of this research study is to compare the effects of a lycopene supplement made from tomatoes to a placebo (a capsule with no active ingredients) in men who have abnormal cells in the prostate, but have not yet had cancer detected. This study will allow us to see if taking lycopene for six months leads to favorable changes in abnormal prostate tissue and in chemicals measured in the blood that go along with a higher risk of developing cancer.


Eligibility Criteria:
Inclusion Criteria:

* Male
* Have a history of prostate biopsy indicating HGPIN without cancer within 2 years prior to registration. At least 4 weeks must have elapsed between the last biopsy and the biopsy used for baseline data.
* Have an AUA symptom score \<=25 at time of registration.
* Refrain from taking lycopene, selenium, vitamin E, or other antioxidant supplements within 1 month of randomization. Participants must agree to refrain from taking non-study dietary supplements while on study
* Refrain from taking exogenous hormones, drugs affecting hormone metabolism, or specified non-prescription substances (e.g. saw palmetto, PC-Spes) taken to affect the prostate within 1 month of registration. Patients must also agree to refrain from taking the non-prescription substances while on study
* Be willing to limit intake of lycopene-containing foods while on study
* Have no prior cancer (except basal cell or squamous cell skin cancer) or complete remission for at least 5 years
* Be ambulatory, capable of self-care and able to carry out light or sedentary work
* Have a dietary fat intake of 23-48% of calories
* Participant's physician recommends repeat biopsy 4-6 months after randomization

Exclusion Criteria:

* No repeat biopsy planned
* Not willing to change diet
* Have a diagnosis of prostate cancer
Expanded Access for Dasatinib

This is an expanded access designed to provide access to dasatinib for eligible participants.


Eligibility Criteria:
Feasibility of Breast Cancer Risk Evaluation in Women From the General Population

This study aims to evaluate the feasibility (acceptability) of a consultation dedicated to informing women about their risk of breast cancer and the screening methods recommended for them according to the recommendations in force during a routine consultation at a general practitioner, a gynecologist or a radiologist.


Eligibility Criteria:
Inclusion Criteria:

* Woman from 40 to 74 years old
* Understanding the French language

Exclusion Criteria:

Women will not be eligible for study if they are in any of the following situations:

* Cancer active or in the course of treatment type surgery, chemotherapy, or radiotherapy, whether breast or other organ
* Recent diagnosis \<1 year of suspicious or cancerous lesions
* Psychiatric pathology not compatible with the study
* Poor understanding of the French language
Better Sleep in Psychiatric Care - Depression, Anxiety and PTSD

Cognitive Behavioral Therapy (CBT) is treatment of choice for insomnia. Many patients in psychiatric care have sleep problems including insomnia, but are rarely given the choice to participate in CBT to improve their sleep. Patients with PTSD, Anxiety disorders and Depression display high levels of sleep difficulties. Sleep problems are often general, such as insomnia and sleep phase problems. In a previous pilot study, the investigators of the current study developed a CBT protocol that would target sleep problems in this mixed psychiatric population. The basis was CBT for insomnia (CBT-i), but also including techniques that would alleviate sleep phase problems (e.g. the systematic use of light and darkness), and techniques to target more general sleep related problems (e.g. difficulties waking up in the morning), that are also common in psychiatric patients. This treatment was well tolerated and gave large withing-group effects on insomnia severity in the pilot study. In a naturalistic randomized controlled trial, the investigators now evaluate the effects of this psychological treatment on sleep and anxiety and depressive symptoms in patients at the units for Anxiety and Affective disorders and Trauma, Southwest Psychiatry and Northern Stockholm Psychiatry, Stockholm County Council, Sweden.


Eligibility Criteria:
Inclusion Criteria:

* Being a patient at the clinics involved in the project
* Experiencing sleep problems (subjective report)
* Being able to participate in a psychological intervention in group format

Exclusion Criteria:

* Night shift work
Saliva and Plasma Exosomes for Oral Leukoplakia Malignant Transformation Diagnosis and Oral Cancer Prognosis Monitoring

The goal of this observational study is to test the expression levels of salivary and plasma exosomal miR-185 in patients with oral leukoplakia and oral squamous cell carcinoma. The main questions it aims to answer are:

* Is it possible to identify the cancer risk of oral leukoplakia in its early stages by detecting salivary and plasma exosomal miR-185?
* Is it possible to monitor the cancer risk of oral leukoplakia and the prognosis of oral cancer using salivary exosomal miR-185?

Participants will be asked to:

* Cooperate with the investigators in completing the oral examination.
* Take saliva and plasma before the biopsy surgery.
* Perform the biopsy surgery following the usual diagnostic procedures.
* Attend regular follow-up appointments (every 3 months) for the duration of the study.

The first part of the study is a cross-sectional study in which the investigators will detect the expression level of salivary exosomal miR-185 in the participants at a single time point. The second part of the study is a prospective cohort study, in which the investigators will conduct regular follow-ups on the participants enrolled in the first part.

Eligibility Criteria:
Inclusion Criteria:

* Males or females aged 30\~80 years.
* Clinical diagnosis consistent with oral leukoplakia and oral cancer.
* Individuals with local stimulating factors correlated with oral lesions (including residual roots, residual crowns, poor oral restorations, cheek biting, and tongue biting habits).
* Oral lesions not subjected to any treatment, including laser, photodynamic therapy, radiotherapy, and chemotherapy.

Exclusion Criteria:

* Pathological diagnosis of another disease rather than oral leukoplakia or squamous cell carcinoma.
* Females who were pregnant or breastfeeding.
* Individuals who had malignancy, severe and precariously controlled diabetes mellitus, episodes of cardiovascular disease, hepatic or renal dysfunction, respiratory disease, hematologic disease, or immune abnormalities in the past year.
* Individuals with a psychiatric disorder.
* Other conditions deemed inappropriate for study participation by the researchers.
Linus Health CDS Retrospective Validation Study

This study is a retrospective validation study of deidentified Clinical Decision Support (CDS) recommendations generated by the Linus Health Core Cognitive Evaluation (CCE) for patients who have completed the CCE.

Site investigators consist of clinical experts including neurologists and geriatricians in the U.S. After signing the study agreements, the experts will receive batches of anonymized CCE outputs of patients and will rate the appropriateness of each CDS recommendation for each patient based on their review of the CCE results and their clinical judgment and expertise. The experts will also rate the clinical appropriateness of various parts of CDS pathways that form the LH CDS decision tree.


Eligibility Criteria:
Inclusion Criteria:

* Age 55 and above
* Has already completed the Linus Health CCE

Exclusion Criteria:

* Incomplete CCEs
* CCEs that are flagged as "Requires clinician review"